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Abstract
Background: Systemic sclerosis (SSc) is a chronic inflammatory autoimmune disease characterised by vascular
dysfunction and damage, excess collagen deposition and subsequent organ manifestations. Vasculopathy is an
early feature of the disease which leads to a chronic hypoxic environment in the tissues. Paradoxically, there is a
lack of angiogenesis. We hypothesised that this may in part be due to a nonphysiological, overriding upregulation
in antiangiogenic factors produced by the hypoxic tissues. We considered thrombospondin 1 (TSP-1) as a
candidate antiangiogenic factor.
Results: Conditioned media from human microvascular endothelial cells cultured in both normoxic and hypoxic
environments were able to block endothelial cell proliferation, with the latter environment having a more
profound effect. Filtration to remove > 100-kDa proteins or heparin-binding proteins from the conditioned media
eliminated their antiproliferative effect. TSP-1 was expressed in high concentrations in the hypoxic media, as was
vascular endothelial growth factor (VEGF). Depletion of TSP-1 from the media by immunoprecipitation reduced the
antiproliferative effect. We then show that, in a dose-dependent fashion, recombinant TSP-1 blocks the proliferation
of endothelial cells. Immunohistochemistry of skin biopsy material revealed that TSP-1 expression was significantly
higher throughout the skin of patients with SSc compared with healthy controls.
Conclusions: Despite the environment of chronic tissue hypoxia in SSc, there is a paradoxical absence of angiogenesis.
This is thought to be due in part to aberrant expression of antiangiogenic factors, including TSP-1. We have
demonstrated that TSP-1 is released in high concentrations by hypoxic endothelial cells. The conditioned media from
these cells is able to block proliferation and induce apoptosis in microvascular endothelial cells, an effect that is reduced
when TSP-1 is immunoprecipitated out. Further, we have shown that recombinant TSP-1 is able to block proliferation
and induce apoptosis at concentrations consistent with those found in the plasma of patients with SSc and that its
effect occurs in the presence of elevated VEGF levels. Taken together, these data are consistent with a model wherein
injured microvascular cells in SSc fail to repair because of dysregulated induction of TSP-1 in the hypoxic tissues.
Background
Systemic sclerosis (SSc) is a chronic inflammatory auto-
immune disease characterised by vascular dysfunction
and damage, excess collagen deposition and subsequent
organ manifestations [1]. The pathogenesis of SSc has
yet to be fully elucidated. Vasculopathy occurs early in
the disease and precedes fibrosis [2]. This is charac-
terised by both abnormal vascular tone and endothelial
cell damage [3]. Endothelial apoptosis is seen in recent-
onset SSc patients’ dermal biopsies [4]. Anti-endothelial
cell antibodies have been detected in some but not all
patients with SSc [5]. These antibodies are capable of
upregulating the expression of endothelial cell adhesion
molecules and inducing apoptosis [6].
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Other sources of early endothelial cell damage include
reactive oxygen species, markers of which are found in
the serum and urine of patients with SSc at higher levels
than in controls [7,8]. In addition, nitric oxide synthesis
by endothelial cells is dysregulated in SSc because of
suppression of the endogenous nitric oxide synthetase
and upregulation of the inducible isoform. Because of
this, proteins and lipids can become damaged in SSc by
oxidation or nitrosylation [9].
Vascular damage clinically manifests in early SSc as Ray-
naud’s phenomenon, sometimes seen many years before
the other features develop [10]. In addition, nailfold capil-
laroscopy is abnormal in early SSc, reflecting the endothe-
lial vascular damage. The characteristic features of nailfold
capillaroscopy in SSc include the presence of abnormal
tortuous microvascular loops, the progressive loss of capil-
lary density and areas of microvascular loss. Despite the
chronic hypoxic environment and increased levels of
proangiogenic vascular endothelial growth factor (VEGF)
and its receptors, there is a failure of endothelial repair
and an absence of angiogenesis in SSc [11,12].
It has been postulated that the failure of angiogenesis
in SSc may be due to a nonphysiological, overriding
influence of antiangiogenic factors, which are present in
high concentrations in the sera of patients with SSc
[13-15]. Furthermore, plasma from patients with SSc has
been shown to inhibit the migration and proliferation of
microvascular endothelial cells [16].
Because of this, we became interested in the idea that
hypoxic tissues are capable of releasing factors which
interfere with reparative angiogenesis. We have gone on
to test whether media from human cells cultured under
hypoxic conditions can interfere with the growth of
endothelial cells and whether the candidate antiangio-
genic factor thrombospondin 1 (TSP-1) is induced in
hypoxic cells or in the involved tissues of SSc patients.
Methods
Cell culture
The extended lifespan simian virus 40 transfected der-
mal human microvascular endothelial cell 1 (HMEC-1)
cell line was employed. This line was generated by Ades
et al. [17] and has been shown to maintain the phenoty-
pic characteristics of small-vessel endothelial cells. For
experiments, HMEC-1 cells were cultured in DMEM
(Autogen Bioclear UK Ltd, Caine, Wiltshire, UK) with
10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate,
100 U/mL penicillin and 100 μg/mL streptomycin.
Cells were examined regularly by using phase contrast
microscopy. Preparations which had reached confluence
were trypsinised for secondary culture. Preparations
which appeared to be infected by bacteria or failed to
reach confluence after five days were discarded. Cells
were passaged at confluence using 10% trypsin and split
into equal thirds. The C2C12 mouse myoblast line 19
was also used. C2C12 cells were cultured on 0.01% gela-
tine plates in DMEM supplemented with 10% FCS, 2
mM L-glutamine, 1 mM sodium pyruvate, 100 U/mL
penicillin and 100 μg/mL streptomycin.
Hypoxic culture
Cells were cultured in a custom-made hypoxic cham-
ber placed within a tissue culture incubator and main-
tained at 37°C. The cells were plated onto 100-mm
tissue culture plates and placed within the chamber,
which had been primed for one hour by flushing with
4% CO2, 1% O2 and 95% N2. The chamber was then
sealed, and hypoxic conditions were maintained for a
further 24 hours prior to removal of the media for
assay. Media were removed at the end of 24 hours of
hypoxic culture for gas analysis and were found to
have the following values (means ± SEM): pH 7.41 ±
0.04, pO2 6.4 ± 0.8 kPa and pCO2 5.2 ± 1.2 kPa. By
comparison, media following culture under standard
normoxic conditions for 24 hours had the following
values (means ± SEM): pH 7.42 ± 0.04, pO2 16.2 ± 1.1
kPa and pCO2 4.8 ± 1.6 kPa.
Endothelial cell proliferation
HMEC-1 cells were harvested at 80% confluence and
plated at 5 × 104 cells/well in 12-well plates, cultured
for 24 hours and then cultured further in the presence
or absence of 10% FCS with or without conditioned
media from endothelial cells or skeletal muscle cells to
test for antiproliferative effects of the conditioned
media. After 24 hours of incubation, the cells were har-
vested by trypsinisation and counted in a haemocyt-
ometer. Each experiment was performed in triplicate.
In further experiments, HMEC-1 cells were cultured
on 96-well plates with or without conditioned media
from endothelial cells or with various concentrations
of recombinant TSP-1 (R&D Systems Minneapolis,
MN, USA). The number of viable cells was measured
by WST-1 assay. In this assay, a tetrazolium dye
undergoes a colour change depending on the presence
of viable mitochondria. Ten microlitres of WST-1 were
added to each well, and the cells were incubated for a
further two hours. The colour intensity was read at
450 nm (reference wavelength 655 nm) in an ELISA
plate reader.
Assay for TSP-1 and VEGF
Media were removed and assayed for TSP-1 and VEGF
by ELISA (R&D Systems Pharmacia Biotech, Little Chal-
font, UK). Experiments were performed in triplicate, and
samples were assayed in duplicate according to the
manufacturer’s instructions. Standard curves were
included in each assay plate.
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Western blot analysis
Western lysate samples of 20 μL containing 10 μg of
protein were run upon a ready-cast 4% to 12% Tris-Gly-
cine gel (Novex. Ontario, Canada) alongside a broad-
range protein marker (New England Biotech, Wakefield,
MA, USA) at 125 V until the dye front had reached the
bottom of the gel (approximately 1.5 hours) in Tris-Gly-
cine Running Buffer (Invitrogen, Carlsbad, CA, USA).
Proteins were electrophoretically transferred to nitrocel-
lulose Hybond-C (Amersham Pharmacia, Little Chal-
fontBuckinghamshire, UK). Each membrane was briefly
washed, and then nonspecific protein binding was
blocked by one-hour incubation with 10% milk protein
in PBS. Membranes were probed with antibodies against
caspase 3 and cleaved caspase 3 (#9662 and #9661S;
New England Biolabs, Wakefield, MA, USA), and bind-
ing was detected using labelled species-specific second-
ary antibody followed by avidin-biotin complex
detection assay (Amersham Pharmacia).
Quantitative RT-PCR analysis
HMEC-1 were cultured to 90% confluence and incu-
bated overnight in hypoxic (1% O2 and 5% CO2) or nor-
mal conditions at 37°C. RNA was extracted from cells
using the RNeasy Kit (Qiagen, Crawley West Sussex,
UK), and the quality was evaluated on the Agilent 2100
Bioanalyzer (Agilent Technologies Edinburgh, UK). One
microgram of RNA extracted from each well was
reverse-transcribed using the QuantiTect Reverse Tran-
scription Kit (Qiagen). qPCR was performed in triplicate
using the SensiMix SYBR kit (Bioline, London, UK) on
the Rotor-Gene 6000 (Qiagen, Crawley West Sussex,
UK), and data were normalised against expression of
TUBB and SDHA. The reference genes were chosen
using genormPLUS software (Biogazelle, Ghent, Nether-
lands). The qRT-PCR conditions were 40 cycles at 95°C
for 10 minutes, 95°C for 10 seconds, 60°C for 15 sec-
onds and 72°C for 20 seconds. The primers used are
shown in Table 1.
Immunohistochemistry
For immunofluorescence, sections were permeabilised
by washing three times in cold PBS containing 0.3% Tri-
ton X-100 at room temperature for 5 minutes, then
washing them further in PBS containing 0.1% Tween.
Nonspecific binding sides were blocked with 3% BSA
and 10% serum in PBS with Tween for 30 minutes. Sec-
tions were immunostained with rabbit polyclonal anti-
TSP-1 antibody (#sc-14013; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) overnight at 4°C. As a negative
control, samples were incubated with polyclonal rabbit
immunoglobulin G (Vector Laboratories, Burlingame,
CA, USA). Sections were incubated with Alexa Fluor
568- or Alexa Fluor 594-labelled anti-rabbit antibody
(Molecular Probes/Invitrogen, Eugene, OR, USA)
(1:1000) for one hour. Nuclei were stained for 4’,6-dia-
midino-2-phenylindole (Sigma-Aldrich, St Louis, MO,
USA) for 10 minutes. Glass coverslips were mounted
onto slides with Vector aqueous anti-fade VECTA-
SHIELD fluorescence mounting medium (Vector
Laboratories) and sealed with nail polish. Sections were
imaged with an Zeiss Axioplan microscope (Carl Zeiss,
Heidenheim, Germany) at ×40 original magnification.
Results
Conditioned media from hypoxic endothelial cells block
proliferation
We began by testing whether media from hypoxic cells
could block cellular proliferation. HMEC-1 endothelial
cells and C2C12 muscle cells were cultured to confluence
in 75-cm2 flasks under normoxic or hypoxic conditions.
After 24 hours, media were removed and transferred to
proliferating HMEC-1 cells grown on six-well plates in
10% FCS. Culture under serum-free conditions was used
as a negative control, and medium plus 10% FCS was
used as a positive control. Conditioned media from
HMEC-1 but not from C2C12 cells inhibited cellular
proliferation. This effect was more marked when condi-
tioned media from hypoxic HMEC-1 cells were used,
and these were found to abolish proliferation (Figure 1).
In addition, cells cultured in media transferred from
hypoxic HMEC-1 cells took on an altered morphology
with more rounding up of cells (Figure 1).
Antiproliferative effect of hypoxia-conditioned media is
due to a heparin-binding macromolecule
Because of the above-described findings, we became
interested in identifying which factor released by
hypoxic HMEC-1 cells was responsible for the suppres-
sion of cell proliferation and for the change in cellular
morphology. Further experiments were performed using
filtration to remove protein factors > 10 kDa and > 100
kDa and using heparin Sepharose beads to precipitate
and remove heparin-binding factors. Media were trans-
ferred to proliferating HMEC-1 cells grown on 96-well
plates, and cell numbers were assayed after 24 hours by
WST-1 assay and imaged using a Zeiss Axio Scope
(Carl Zeiss). Filtration to remove > 10-kDa factors was
found to eliminate the antiproliferative effect of
Table 1 Primers used for qRT-PCR
Gene Primer Sequence
THBS1 Forward
Reverse
CTGACCTGAAATACGAATGTAGAGA
TTTCTCAAGCCCATAGTTCCAGAAG
TUBB Forward
Reverse
ACATACCTTGAGGCGAGCAA
TCACTGATCACCTCCCAGAA
SDHA Forward
Reverse
AGAAGCCCTTTGAGGAGCA
CGATCACGGGTCTATATTCCAGA
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hypoxia-conditioned media and to block the morpholo-
gical changes induced (Figure 2). Because of this, we
concluded that the effects were not simply due to degra-
dation of the hypoxia-conditioned media. Filtration of >
100-kDa factors was also found to abolish the antiproli-
ferative effects of hypoxia-conditioned media (Figure 2).
In addition, removal of heparin-binding proteins using
heparin Sepharose beads led to loss of the antiprolifera-
tive effect of the media (Figure 2). We concluded that
the antiproliferative effect of the hypoxia-conditioned
media was due to the presence of heparin-binding
macromolecules > 100 kDa.
TSP-1 is induced in hypoxia-conditioned media and
blocks proliferation of HMEC-1 cells
Because we found that the antiproliferative effects were
due to the presence of a large heparin-binding factor,
and because TSP-1 is believed to promote endothelial
cell apoptosis, we considered TSP-1 as a candidate fac-
tor responsible for the antiproliferative effect and change
in cellular morphology induced by hypoxia-conditioned
media. We assayed levels of TSP-1 in media from
HMEC-1 cells grown under normoxic and hypoxic con-
ditions. TSP-1 was present in the media of normoxic
HMEC-1 cells and was induced following 24 hours in
hypoxic culture (mean ± SEM TSP-1 in normoxic
HMEC-1 media 569 ± 37 ng/mL, mean ± SEM TSP-1
in hypoxic HMEC-1 media 775 ± 25 ng/mL; P < 0.004)
(Figure 3). As expected, the hypoxic culture conditions
led to an induction of VEGF, and levels of VEGF were
increased in the hypoxic HMEC-1 media (mean ± SEM
VEGF in normoxic HMEC-1 media 184 ± 54 pg/mL,
mean ± SEM VEGF in hypoxic HMEC-1 media 447 ±
22 pg/mL, SEM; P < 0.01) (Figure 3).
In addition, TSP-1 mRNA levels in HMEC-1 cells cul-
tured under normoxic and hypoxic conditions were
assayed by qRT-PCR. Culture under hypoxic conditions
for 24 hours led to the induction of TSP-1 expression
(mean ± SEM normoxic cell TSP-1 copy number 3.19 ±
0.41, mean ± SEM hypoxic culture copy number 8.98 ±
2.39; P < 0.0035) (Figure 3).
Next we measured whether recombinant TSP-1 is able
to block the proliferation of HMEC-1 cells. TSP-1
blocked, in a dose-dependent fashion, the proliferation
Figure 1 Conditioned media from hypoxic endothelial cells inhibit proliferation. Human microvascular endothelial cell 1 (HMEC-1) cells
and C2C12 muscle cells were grown to confluence and then cultured further under normoxic or hypoxic conditions. Media were transferred
undiluted to rapidly proliferating HMEC-1 cells in the presence of 10% FCS. Culture in DMEM with 10% FCS was used as a positive control, and
culture with 10 μM mitomycin C added at baseline to block proliferation was used as a negative control. After 24 hours, further culture
proliferation of HMEC-1 cells was measured using a haemocytometer, and the cells were imaged. (a) Exposure to conditioned media from
HMEC-1 cells, but not from C2C12 cells, inhibited proliferation (results are expressed as total number of cells per well of a six-well plate/10
-4). (b)
Effects were more marked with media from hypoxic HMEC-1 cells which abolished proliferation and caused rounding up of the cells.
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of HMEC-1 cells grown on 96-well plates in the pre-
sence of 10% FCS (Figure 4). Full suppression of prolif-
eration was seen with 100 ng/mL TSP-1 and partial
suppression was observed with 50 ng/mL TSP-1. In
addition, immunoprecipitation of TSP-1 from condi-
tioned media blocked some but not all of the antiproli-
ferative effect (Figure 2). Because we suspected that
TSP-1 and hypoxia-conditioned media were causing
apoptosis, we measured the effect of TSP-1 and
hypoxia-conditioned media on cleaved caspase 3 levels
in HMEC-1 cells. Both TSP-1 and hypoxia-conditioned
media led to increased levels of cleaved caspase 3 in
HMEC-1 cells after 16 hours of culture (Figure 4). We
concluded that TSP-1 is induced following culture of
HMEC-1 cells in hypoxia and that TSP-1 blocks the
proliferation of HMEC-1 cells and causes apoptosis,
despite the elevation of VEGF.
TSP-1 is expressed by endothelial cells in normal skin and
is induced in SSc-involved tissues
Because of the above-described findings, we became
interested in the idea that similar effects might be
occurring in SSc patients and that TSP-1 might be
induced in the ischaemia-involved SSc tissues. We
next performed immunohistochemistry to stain healthy
control skin biopsy material and SSc-involved forearm
Figure 2 Suppression of proliferation by endothelial cell-conditioned media is due in part to presence of heparin-binding
macromolecule. (a) In further experiments, HMEC-1 were cultured on 96-well plates in the presence of 10% FCS to promote proliferation.
Treatment with mitomycin C at baseline was used as a negative control. Addition of conditioned media from hypoxic HMEC-1 blocked
proliferation. (b) Filtration to remove molecules > 10 kDa, or heparin binding molecules blocked the effect of hypoxia conditioned media on
morphology of treated cells. (c) In further experiments, filtration was used to remove molecules > 100 kDa or (d) immunoprecipitation of TSP-1
antagonised the antiproliferative effects of the conditioned media.
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skin for the presence of TSP-1 using a monoclonal
anti-TSP-1 antibody. In healthy control skin, positive
staining for TSP-1 was seen in the dermal microvascu-
lature but was otherwise absent. By contrast, in SSc-
involved skin, TSP-1-positive staining was observed in
endothelial cells, epidermal keratinocytes and dermal
connective tissue cells (Figure 5). We concluded that
TSP-1 was being induced in the SSc dermis and
epidermis.
Also, we wanted to test whether free TSP-1 was pre-
sent in the dermal interstitial fluid sampled from SSc
and healthy control skin. In fact, in dermal interstitial
fluids, TSP-1 was present only at very low levels and
appeared absent from SSc dermal fluid (data not
shown). We concluded that while TSP-1 was abundant
within the dermis and epidermis in SSc, it was present
only at low levels as a free, non-matrix-associated factor
in the extracellular fluid.
Discussion
Hallmarks of SSc are tissue ischaemia due to vascular
injury, remodelling and stenosis; increased vascular tone;
and microvascular damage. Despite the endothelial cell
damage and activation and the ensuing chronic hypoxic
environment, there is a failure of angiogenesis in SSc. It
has been hypothesised that this might be due in part to
an aberrant expression of antiangiogenic factors, and we
have sought to investigate further the antiangiogenic
effects of TSP-1 in the disease.
TSP-1 is derived from a large trimeric glycoprotein and
functions as an adhesive matricellular factor modifying
the binding of a variety of cells to extracellular matrix
proteins [18,19]. TSP-1 has multiple binding sites, includ-
ing an amino terminal heparin-binding domain, a procol-
lagen domain, epidermal growth factor-like repeats and
Figure 3 Induction of VEGF and TSP-1 in the media of HMEC-1
cells cultured under hypoxic conditions. Conditioned media from
confluent HMEC-1 grown under normoxic or hypoxic culture
conditions were assayed by ELISA for VEGF and TSP-1. Hypoxic
culture (24 hours) was associated with increased levels of both (a)
VEGF (mean ± SEM VEGF in normoxic conditions 184 ± 54 pg/mL,
mean ± SEM VEGF in hypoxic conditions 447 ± 22 pg/mL; P < 0.05)
and (b) TSP-1 (mean ± SEM TSP-1 in normoxic conditions 569 ± 37
pg/mL, mean ± SEM TSP-1 in hypoxic conditions 775 ± 24.5 pg/mL;
P < 0.003). (c) In addition, TSP-1 mRNA levels were assayed by
performing qRT-PCR. Hypoxic culture led to increased TSP-1 mRNA
levels (mean ± SEM TSP-1 copy number in normoxia 3.19 ± 0.41,
mean ± SEM TSP-1 copy number in hypoxia 8.98 ± 2.39; P < 0.004).
Figure 4 Addition of recombinant TSP-1 to proliferating endothelial cells blocks proliferation and induces apoptosis. (a) Recombinant
human TSP-1 was added to rapidly proliferating HMEC-1 cells grown on 96-well plates in the presence of 10% FCS, and cell numbers were
assessed by performing a WST-1 assay after 24 hours of further culture. The addition of TSP-1 suppressed proliferation in a dose-dependent
manner. (b) In other experiments, proliferating HMEC-1 cells were treated with TSP-1 or conditioned media from cultured HMEC-1 cells and then
lysed after 16 hours for Western blot analysis for cleaved caspase 3. Exposure to both TSP-1 and hypoxia-conditioned media led to elevation of
cleaved caspase 3 in the cells, consistent with the induction of apoptosis. *P < 0.04. **P < 0.03.
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an RGD (arginine-glycine-aspartic acid) integrin-binding
region [20]. The binding of TSP-1 to fibronectin, fibrino-
gen, laminin and collagen 5 has been described [21,22].
TSP-1 is released from granules of platelets, from
endothelial cells and from other cells, including keratino-
cytes and fibroblasts [23,24]. Diverse functions of TSP-1
have been defined, including the adhesion of platelets to
thrombin-containing clots, targeting of cells for apoptosis
and clearance of apoptotic cells by macrophages [25].
Studies of TSP-1-knockout mice have demonstrated that
wounds heal more slowly and irregularly because of pro-
longed inflammation, delayed closure, scab loss and ree-
pithelialisation. In hindlimb ischaemia in the TSP-1-
knockout mice, enhanced angiogenesis and improved
blood flow were shown [26,27].
We were interested to find that when media from
microvascular human endothelial cells cultured in
hypoxia were added to proliferating endothelial cells,
proliferation was blocked and apoptosis was induced.
These effects were not observed when media from
hypoxic muscle cells were used. This suggests the pre-
sence of a factor released by the hypoxic endothelial
cells which was blocking proliferation. This effect was
reduced by diluting the conditioning media, removing
proteins that bind heparin and filtering large molecular
weight proteins. This led us to consider whether TSP-
1, a large glycoprotein with a heparin-binding domain,
was a component of the culture media contributing to
its antiproliferative and apoptotic effect. In keeping
with this idea, we found that the concentration of
TSP-1 was increased in media from hypoxic endothe-
lial cells compared with normoxic endothelial cells and
that TSP-1 mRNA levels were induced by hypoxic cul-
ture. Also, depletion of TSP-1 by immunoprecipitation
partially blocked the inhibition of proliferation. These
data are consistent with those in previous studies
showing that TSP-1 can induce apoptosis of cells and
that TSP-1 is hypoxia-inducible under some culture
conditions [28,29]. Furthermore, when we directly trea-
ted proliferating endothelial cells with recombinant
TSP-1, there was suppression of proliferation and
induction of apoptosis.
We also have shown that there is more TSP-1
expressed in the dermis and epidermis of patients with
SSc than in healthy controls, with staining in keeping
with the presence of TSP-1 in keratinocytes and dermal
connective tissue. These results are consistent with pub-
lished data showing that TSP-1 is elevated in SSc [15].
Interestingly, the plasma levels of TSP-1 seen in SSc
(mean ± SEM TSP-1 27.2 ± 8.5 ng/mL) are close to the
levels that we found blocked endothelial cell prolifera-
tion and induced apoptosis in cultured endothelial cells.
One interesting result is that despite the induction of
VEGF in hypoxia-conditioned media, which would be
expected to support cell survival and proliferation, the
increased levels of TSP-1 were able to override these
protective effects. In support of this idea, TSP-1 has
recently been shown to modulate the responses of
endothelial cells to VEGF via interaction with the VEGF
type 2 receptor [30].
TSP-1 has been studied previously in SSc and TSP-1
gene expression in skin correlates with severity of skin
involvement in SSc and has been used in combination
with other factors as a biomarker for the disease process
[31]. In SSc and control fibroblasts, TSP-1 is induced by
culture under hypoxic conditions [32]. In addition, TSP-
1 activates the latent complex of transforming growth
factor b (TGFb) and maintains an autocrine loop of sti-
mulation in SSc fibroblast by TGFb [33]. It seems likely
that TSP-1-dependent effects occur in the hypoxic
microenvironment of SSc and that TSP-1 contributes to
the microvascular injury and failure of repair and/or
angiogenesis, despite the elevation of VEGF in the
disease.
Conclusions
Taken together, our data are consistent with a model
wherein injured microvascular cells in SSc fail to repair
because of dysregulated induction of TSP-1 in the
hypoxic tissues. Antiangiogenic factors can be targeted
in future therapeutic approaches, both in SSc and in
Figure 5 TSP-1 is increased in the involved forearm skin of SSc
patients. Skin biopsies from SSc patients and healthy controls (n =
5 for each group) were stained by immunohistochemistry using a
primary antibody against TSP-1. In healthy controls, positive staining
was seen around endothelial cells in the dermis. In SSc sections,
TSP-1 was increased and expressed in endothelial cells, epidermal
keratinocytes and cells of the dermis. Isotype-matched antirabbit
IgG polyclonal antibody was included as a control.
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peripheral vascular disease, where TSP-1 is also induced
and blocks microvascular repair [34].
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